• FDA cleared once-weekly Leqembi Iqlik subcutaneous injection as a starting dose for early Alzheimer’s disease, expanding lecanemab beyond IV initiation.
• Eisai plans a U.S. launch in late August 2026; regimen starts at 500 mg weekly via autoinjector.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607132242PR_NEWS_EURO_ND__EN03698) on July 14, 2026, and is solely responsible for the information contained therein.